Immix Biopharma Reports 89% Complete Response Rate in NEXICART-2, Potential to Reach 98%
IMMX has more than doubled off its 52-week low of $1.99.
Summary
An 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity suggesting the rate could reach 98%. No relapses or serious safety signals were observed. Final readout and BLA submission are planned for mid-2027.
Key Events · Product Development and Regulatory · IMMX
-
89% Complete Response Rate
Across all 45 relapsed/refractory AL Amyloidosis patients in the Phase 2 NEXICART-2 trial, NXC-201 produced an 89% (40/45) complete response rate as assessed by an independent review committee.
-
MRD-Negativity Suggests 98% Potential
All 25 new patients are either in CR or MRD-negative. In four pending patients already MRD-negative, bone marrow MRD-negativity predicts future CR, potentially increasing the CR rate up to 98% (44/45).
-
No Relapses or Serious Safety Signals
No relapses have been observed for any patient who reached CR or MRD-negativity. No neurotoxicity or enterocolitis has been observed to date, with safety data consistent with prior reports.
-
Registrational Path to BLA
NEXICART-2 is a fully enrolled, 45-patient multi-site U.S. Phase 2 trial with a registrational design. Final readout and BLA submission are planned for mid-2027.
Analysis · IMMX · Life Sciences
Interim data from the fully enrolled 45-patient Phase 2 NEXICART-2 trial show an 89% complete response rate in relapsed/refractory AL Amyloidosis, with MRD-negativity suggesting the rate could climb to 98%. An independent review committee assessed the results, and no relapses, neurotoxicity, or enterocolitis have been observed to date. This registrational-design trial supports a final readout and BLA submission in mid-2027. For a company with a $820M market cap and $232M in cash, this data meaningfully de-risks the lead asset and supports a potential best-in-class profile in a $6.6B market.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $11.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $820.6M. The 52-week trading range was $1.99 to $15.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.